Pharmaceutical Equipment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Pharmaceutical Equipment Market Trends and Insights

Rising Biologics Manufacturing Volumes

Biologics commanded 85% of pipeline manufacturing runs in 2024, pushing installed global bioreactor volume from 6.7 million L to an expected 8.9 million L by 2028^{[1]BioPlan Associates, “Biomanufacturing Capacity Report 2024,” bioplanassociates.com} . Viral-vector lines are most constrained, with 18-24-month equipment lead times that limit gene-therapy launches. New product pipelines encourage co-location of upstream and fill-finish assets, trimming batch transfer by 40% and simplifying contamination control^{[2]BioPhorum, “Single-Use Bioprocessing Adoption Trends 2024,” biophorum.com}.

Accelerated Adoption of Single-Use Technologies

Single-use systems reached USD 27.8 billion in 2025 and are now deployed in 62% of commercial batches, saving users millions in cleaning-validation downtime. CDMOs value the 14-day campaign changeovers versus 45-60 days for stainless-steel lines, unlocking higher asset utilization. Supply-chain fragility persists: a 2024 polymer-film plant fire disrupted bag deliveries for 4 months and raised spot prices by 15% across Europe.

Stringent GMP-Driven Equipment Upgrades

The EU Annex 1 update mandates isolators or RABS for aseptic manufacture, generating USD 2.4-3.6 billion in retrofit demand between 2024-2026^{[3]European Medicines Agency, “EU GMP Annex 1 Revision,” ema.europa.eu}. U.S. guidance on advanced technologies layers extra sensors for real-time parameter monitoring, lifting compliance investment for mid-tier biotech to 12-15% of annual revenue, compared with <2% for large multinationals^{[4]U.S. FDA, “Advanced Manufacturing Technologies Designation Program 2024,” fda.gov} .

Expansion of Contract Manufacturing Capacity

CDMOs controlled 28% of installed bioreactor volume in 2024 and booked 52% of equipment orders above USD 10 million, leveraging scale to negotiate 15-20% price concessions. Samsung Biologics, Lonza, and Fujifilm Diosynth together pledged USD 8.4 billion to expand capacity by 3.2 million L and add 14 fill-finish lines by 2026.

High Capital Investment & Long Payback

A greenfield 4×2,000 L biologics plant costs USD 300-450 million and takes seven to nine years to recover at present utilization and pricing. Rising European energy tariffs added USD 2.5-4 million in electricity spends for 10,000 m² facilities in 2024. Modular designs such as Cytiva’s FlexFactory shave 40% off upfront capital but cap annual throughput at 200 kg versus up to 800 kg for traditional builds.

Supply-Chain Shortages of Critical Components

Single-use systems depend on a small pool of polymer-film, filter, and tubing vendors; a March 2024 factory fire in Germany halted bag supplies for four months, forcing batch delays at three CDMOs. Semiconductor bottlenecks lengthened PLC and HMI lead times to 12-16 months at Siemens and Rockwell Automation in 2024. Manufacturers now dual-source 42% of critical items, raising procurement budgets 8-12%

Segment Analysis

By Equipment Type: Aseptic Systems Lead, Quality Instruments Accelerate

Aseptic fill-finish platforms captured 29.55% of the pharmaceutical equipment market share in 2025 amid the boom in pre-filled syringes and autoinjectors for GLP-1 agonists and monoclonal antibodies. Quality-control instrumentation is forecast to grow 4.85% annually through 2031 as regulators require 100% visual inspection and real-time release testing. Upstream bioprocess skids benefit from a 33% surge in mammalian capacity, yet Chinese vendors undercut Western prices by up to 40%, squeezing margins. 

Downstream purification assets, a gating step, run at >85% utilization in leading CDMOs, with each 2,000 L batch cycling through 8-12 chromatography passes and consuming 4-6 hours per pass. Serialization mandates raise primary and secondary packaging line costs by USD 1.5-2.5 million per installation, while Annex 1 drives higher HVAC and water-for-injection expenditure. The pharmaceutical equipment market size tied to lyophilizers and homogenizers trails the broader average as oral-solid dose output migrates to lower-cost sites.

Note: Segment shares of all individual segments available upon report purchase

By Manufacturing Stage: Drug Substance Dominates, QC Testing Surges

Drug substance assets accounted for 36.53% of the pharmaceutical equipment market in 2025, thanks to the capital-intensive nature of bioreactors and fermenters. The fastest growth, at a 5.75% CAGR to 2031, is in quality-control suites, where process analytical technology (PAT) is a precondition for continuous operation licenses. Drug product formulation grows modestly as portfolios shift from tablets to injectables that skip complex coating or granulation steps. Fill-finish capacity bifurcates between 400-600-unit-per-minute high-speed lines for biosimilars and 20-40-unit boutique lines priced at a premium for cell-therapy batches.

By End User: CDMOs Outpace Big Pharma in Growth Velocity

Big Pharma held 42.15% of expenditure in 2025, securing 15-20% volume discounts through global sourcing contracts. CDMOs and CMOs, however, expand faster at 5.82% CAGR, reflecting innovators’ appetite to outsource late-stage and commercial runs for balance-sheet agility. Academic and government sites receive pandemic-preparedness funding, with BARDA channeling USD 4.2 billion into modular suites that can switch products within weeks.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America accounted for 42.52% of the pharmaceutical equipment market revenue in 2025, supported by 3.1 million L of installed bioreactor volume and expedited FDA reviews that shorten approval cycles by up to 9 months. BARDA investments establish rapid-deployment modules in Texas, North Carolina, and Maryland, while Canada’s USD 370 million regenerative-medicine hub enhances clinical-stage capacity. Mexico leverages labor savings of 40-50% to attract three U.S. fill-finish expansions.

Asia-Pacific is projected to grow 5.12% CAGR through 2031, spearheaded by China’s 1.2 million L capacity boost and India’s INR 150 billion PLI incentives for APIs and biologics. South Korea and Singapore host major CDMO clusters, whereas Japan automates to offset labor deficits, implementing 18 collaborative robots across inspection cells.

Europe faces elevated energy costs, with German electricity tariffs up 22% in 2024, yet it remains the innovation nucleus for single-use components, housing 9 of the top 15 suppliers. Annex 1 drives a USD 3 billion retrofit boom, led by Germany, the UK, and France. Southern Europe is emerging as a biosimilar fill-finish hub, driven by lower labor costs, despite slightly longer regulatory timelines. Middle East–Africa and South America remain small but strategically important. Saudi Arabia commits USD 3.2 billion to cut drug import reliance to 50% by 2030. South Africa’s Biovac secured Pfizer partnership for mRNA fill-finish, the continent’s first WHO-prequalified line. Brazil’s state-run Biomanguinhos installed a 2,000 L single-use reactor in 2025, but under-investment in quality control curbs export readiness.